Transforming Conventional to Digital Pathology, Leica Biosystems Introduces Case Management Software to Support Aperio AT2 DX System for Primary Diagnosis

VISTA, Calif.—Mar 2, 2020—Leica Biosystems, a globally recognized cancer diagnostics and workflow solution leader, today announced a significant development for anatomical pathology laboratories by bringing together its Aperio AT2 DX System—digital pathology whole slide imaging—with Aperio Path DX, a web-based, state-of-the-art, case management software.

“Digital pathology has entered the clinical environment with the goal of improving efficiencies, streamlining laboratory workflows, and expanding pathology services,” stated Dan Schrock, Vice President, Clinical Affairs for Leica Biosystems. “Our solution enables clinical labs to produce and digitally deliver consistent, high-quality images the pathologist can confidently rely on to perform routine histologic diagnosis for their patients.”

Aperio Path DX offers tailored software workflows for histotechnicians and pathologists, including quality control, case assembly, assignment and review. It provides a secure digital workstream from the pathology lab to the pathologist’s desk, supporting the on-screen primary diagnosis capabilities of the Aperio AT2 DX System.

“Through continued innovation across the pathology workflow, we have incorporated the comprehensive clinical and operational expertise that redefines efficiency,“ said Melissa Aquino, President of Leica Biosystems. “We are focused on developing novel technologies that accelerate and connect the cancer diagnostics workflow with a vision to deliver high quality patient results within 24 hours.”

About Leica Biosystems
Leica Biosystems (LeicaBiosystems.com) is a cancer diagnostics company and a global leader in workflow solutions, offering the most comprehensive portfolio from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is headquartered in Germany and operates in over 100 countries.